The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia

References

• Baigent C, Keech A, Kearney PM, . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267–78
   PubMed Web of Science ®Google Scholar
• Lewington S, Whitlock G, Clarke R, . Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370:1829–39
   PubMed Web of Science ®Google Scholar
• Teng B, Thompson GR, Sniderman AD, . Composition and distribution of low density lipoprotein fractions in hyperapobetalipoproteinemia, normolipidemia, and familial hypercholesterolemia. Proc Natl Acad Sci U S A 1983; 80:6662–6
   PubMed Web of Science ®Google Scholar
• Gazi IF, Tsimihodimos V, Tselepis AD, . Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opin Biol Ther 2007; 7:53–72
   PubMed Web of Science ®Google Scholar
• Gardner CD, Fortmann SP, Krauss RM. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996; 276:875–81
   PubMed Web of Science ®Google Scholar
• St-Pierre AC, Cantin B, Dagenais GR, . Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005; 25:553–9
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Blazing MA, King TR, . Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004; 93:1487–94
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, . The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 2005; 21:959–69
   PubMed Web of Science ®Google Scholar
• Daskalopoulou SS, Mikhailidis DP. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe. Curr Med Res Opin 2006; 22:511–28
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, . Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23:2009–26
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Gazi I, . Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 2007; 23:1169–76
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Saougos V, . Effect of ezetimibe on lipoprotein subfraction concentrations: the role of atorvastatin pretreatment. Arch Med Sci 2007; 3:344–50
   Web of Science ®Google Scholar
• Despres JP. Cardiovascular disease under the influence of excess visceral fat. Crit Pathw Cardiol 2007; 6:51–9
   PubMedGoogle Scholar
• Whitlock G, Lewington S, Mhurchu CN. Coronary heart disease and body mass index: a systematic review of the evidence from larger prospective cohort studies. Semin Vasc Med 2002; 2:369–81
   PubMedGoogle Scholar
• Davidson MH, Hauptman J, DiGirolamo M, . Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281:235–42
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Kiortsis DN, Liberopoulos EN, . A review of the metabolic effects of sibutramine. Curr Med Res Opin 2005; 21:457–68
   PubMed Web of Science ®Google Scholar
• Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005; 31:15–22
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Kiortsis DN, Liberopoulos EN, . Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study. Curr Med Res Opin 2005; 21:1997–2006
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Gazi IF, Liberopoulos EN, . The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 2007; 193:428–37
   PubMed Web of Science ®Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143–421
   PubMed Web of Science ®Google Scholar
• Bairaktari ET, Seferiadis KI, Elisaf MS. Evaluation of methods for the measurement of low-density lipoprotein cholesterol. J Cardiovasc Pharmacol Ther 2005; 10:45–54
   PubMed Web of Science ®Google Scholar
• Gazi I, Lourida ES, Filippatos T, . Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 2005; 51:2264–73
   PubMed Web of Science ®Google Scholar
• Tselepis AD, John Chapman M. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002; 3:57–68
   PubMed Web of Science ®Google Scholar
• Filippatos TD, Derdemezis CS, Gazi IF, . Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31:53–65
   PubMed Web of Science ®Google Scholar
• Davis HR, Veltri EP. Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb 2007; 14:99–108
   PubMed Web of Science ®Google Scholar
• Huff MW, Pollex RL, Hegele RA. NPC1L1: evolution from pharmacological target to physiological sterol transporter. Arterioscler Thromb Vasc Biol 2006; 26:2433–8
   PubMed Web of Science ®Google Scholar
• Sweeney ME, Johnson RR. Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials. Expert Opin Drug Metab Toxicol 2007; 3:441–50
   PubMed Web of Science ®Google Scholar
• Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003; 91:961–4
   PubMed Web of Science ®Google Scholar
• Reitsma JB, Castro Cabezas M, de Bruin TW, . Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metabolism 1994; 43:293–8
   PubMed Web of Science ®Google Scholar
• Muls E, Kolanowski J, Scheen A, . The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001; 25:1713–21
   PubMed Web of Science ®Google Scholar
• Mittendorfer B, Ostlund Jr RE, Patterson BW, . Orlistat inhibits dietary cholesterol absorption. Obes Res 2001; 9:599–604
   PubMedGoogle Scholar
• Gazi IF, Mikhailidis DP. Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview. Expert Opin Ther Targets 2006; 10:851–66
   PubMed Web of Science ®Google Scholar
• Gill JM, Brown JC, Caslake MJ, . Effects of dietary monounsaturated fatty acids on lipoprotein concentrations, compositions, and subfraction distributions and on VLDL apolipoprotein B kinetics: dose-dependent effects on LDL. Am J Clin Nutr 2003; 78:47–56
   PubMed Web of Science ®Google Scholar
• Wilkinson P, Leach C, Ah-Sing EE, . Influence of alpha-linolenic acid and fish-oil on markers of cardiovascular risk in subjects with an atherogenic lipoprotein phenotype. Atherosclerosis 2005; 181:115–24
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7–22
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR, . Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361:1149–58
   PubMed Web of Science ®Google Scholar
• Lamarche B, Tchernof A, Moorjani S, . Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95:69–75
   PubMed Web of Science ®Google Scholar
• Otvos JD, Collins D, Freedman DS, . Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006; 113:1556–63
   PubMed Web of Science ®Google Scholar
• Sartorio A, Lafortuna CL, Vangeli V, . Short-term changes of cardiovascular risk factors after a non-pharmacological body weight reduction program. Eur J Clin Nutr 2001; 55:865–9
   PubMed Web of Science ®Google Scholar
• Noakes M, Keogh JB, Foster PR, . Effect of an energy-restricted, high-protein, low-fat diet relative to a conventional high-carbohydrate, low-fat diet on weight loss, body composition, nutritional status, and markers of cardiovascular health in obese women. Am J Clin Nutr 2005; 81:1298–306
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, . Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937–52
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, . XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27:155–61
   PubMed Web of Science ®Google Scholar
• Gonzalez-Ortiz M, Martinez-Abundis E, Kam-Ramos AM, . Effect of ezetimibe on insulin sensitivity and lipid profile in obese and dyslipidaemic patients. Cardiovasc Drugs Ther 2006; 20:143–6
   PubMed Web of Science ®Google Scholar
• Gazi IF, Daskalopoulou SS, Nair DR, . Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin 2007; 23:2183–92
   PubMed Web of Science ®Google Scholar
• Athyros VG, Elisaf M, Papageorgiou AA, . Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis 2004; 43:589–99
   PubMed Web of Science ®Google Scholar
• Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology 2007; 132:2191–207
   PubMed Web of Science ®Google Scholar
• Assy N, Hussein O, Abassi Z. Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis. Gut 2007; 56:443–4
   PubMed Web of Science ®Google Scholar
• Kim DJ, Noh JH, Cho NH, . Serum gamma-glutamyltransferase within its normal concentration range is related to the presence of diabetes and cardiovascular risk factors. Diabet Med 2005; 22:1134–40
   PubMed Web of Science ®Google Scholar
• Lee DS, Evans JC, Robins SJ, . Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007; 27:127–33
   PubMed Web of Science ®Google Scholar
• Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002; 20:1873–8
   PubMed Web of Science ®Google Scholar
• Tzotzas T, Filippatos TD, Triantos A, . Effects of a low-calorie diet associated with weight loss on lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) activity in healthy obese women. Nutr Metab Cardiovasc Dis 2007. (Epub ahead of print)
   PubMed Web of Science ®Google Scholar
• Saougos VG, Tambaki AP, Kalogirou M, . Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 2007; 27:2236–43
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Hoogeveen RC, Bang H, . Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2004; 109:837–42
   PubMed Web of Science ®Google Scholar
• Oei HH, van der Meer IM, Hofman A, . Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 2005; 111:570–5
   PubMed Web of Science ®Google Scholar